Non-invasive imaging biomarkers for nonalcoholic steatohepatitis (NASH) clinical drug development are widely used to study the effects of investigational products on the degree of steatosis, inflammation and fibrosis of the liver. This webinar will discuss the selection and application of imaging modalities to measure target engagement and mechanism-of-action in metabolically active organs, including the liver, adipose tissue, pancreas, skeletal muscle, heart and kidney, when designing and conducting NASH clinical trials.
This webinar is the first in a collaborative series hosted by ProSciento, Inc. and the NASH Roundtable™ and focused on the advancement and application of scientific methods and strategies for NASH clinical research.
Topics discussed in the webinar:
- Non-invasive imaging techniques for NASH clinical drug development including MRI, MRE, MRS, PET, and ultrasound, including FibroScan
- The use of non-invasive imaging to measure disease activity, disease staging, target engagement and mechanism-of-action in NASH clinical trials
- Innovations in structural and functional imaging of major metabolically active organs beyond the liver, including adipose tissue, pancreas, skeletal muscle, heart and kidney
- Advantages and limitations of imaging in NASH clinical drug development including cost, availability, pathophysiological relevance, accuracy and suitability for repeat measurements
Chief Medical Officer, ProSciento, Inc.
Dr. Linda Morrow is Chief Medical Officer at ProSciento, Inc. Her career in clinical research and drug development for NASH, diabetes and obesity spans more than 25 years and includes contributions to many diabetes and related metabolic drugs and devices on the market globally today. Dr. Morrow has been the principal investigator on more than 80 clinical research studies for metabolic small and large molecule therapies, biologics, biosimilars and devices. She is an author on more than 50 peer-reviewed articles and book chapters. Dr. Morrow is also a frequent presenting speaker at medical and industry conferences, including keynote presentations at the NASH Summit.
Chief Scientific Officer, Antaros Medical AB
Dr Johansson is Chief Scientific Officer and co-founder of Antaros Medical AB, an advanced clinical imaging research and methodology company. Dr. Johansson is recognized as a leading expert in innovative MRI and PET imaging techniques as biomarkers indicative of disease activity and therapeutic responses in cardiometabolic clinical research, including NASH. He has authored more than 150 peer-reviewed publications in the cardiovascular and metabolism field, with a primary focus on imaging. His experience in drug development includes a 10-year tenure at AstraZeneca, where he was Senior Principal Scientist, involved in projects ranging from pre-clinical to life cycle management. Dr. Johansson has led a large number of international multi-center imaging trials, including principle investigator on international grants from EU, JDRF, NIH and EFSD. Dr. Johansson frequently presents at industry conferences, including keynote presentations at the NASH Roundtable and the NASH Summit.
Who Should Attend?
It is intended for professionals, scientists and educators of all levels interested in learning from leading experts about clinical trial design and current and emerging imaging techniques for NASH/NAFLD drug development.